Literature DB >> 22676247

Synthesis and biological evaluation of 1-benzylidene-3,4-dihydronaphthalen-2-one as a new class of microtubule-targeting agents.

Jia Liu1, Can-Hui Zheng, Xiao-Hui Ren, Feng Zhou, Wei Li, Ju Zhu, Jia-Guo Lv, You-Jun Zhou.   

Abstract

A series of 1-benzylidene-3,4-dihydronaphthalen-2-one derivatives were designed and synthesized, and their biological activities in vitro and in vivo were evaluated. The results showed a number of the title compounds exhibiting potent nanomolar activity in several human cancer cell lines. Of these, compound 22b showed the strongest inhibitory activity against human CEM, MDA-MBA-435, and K562 cells (IC(50) = 1 nM), displayed in vitro inhibition of tubulin polymerization (IC(50) = 3.93 μM), and significantly induced cell cycle arrest in G2/M phase. In addition, compound 22b could inhibit the tumor growth in colon nude mouse xenograft tumor model significantly and seemed safer than CA-4 when achieving a similar tumor suppression. This study provided a new molecular scaffold for the further development of antitumor agents that target tubulin.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22676247     DOI: 10.1021/jm300596s

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  2 in total

1.  Design, synthesis, and biological evaluation of (E)-N-aryl-2-arylethenesulfonamide analogues as potent and orally bioavailable microtubule-targeted anticancer agents.

Authors:  M V Ramana Reddy; Muralidhar R Mallireddigari; Venkat R Pallela; Stephen C Cosenza; Vinay K Billa; Balaiah Akula; D R C Venkata Subbaiah; E Vijaya Bharathi; Amol Padgaonkar; Hua Lv; James M Gallo; E Premkumar Reddy
Journal:  J Med Chem       Date:  2013-06-25       Impact factor: 7.446

2.  Novel harmine derivatives for tumor targeted therapy.

Authors:  Siwen Li; Aqin Wang; Fan Gu; Zhaohui Wang; Caiping Tian; Zhiyu Qian; Liping Tang; Yueqing Gu
Journal:  Oncotarget       Date:  2015-04-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.